- Quote, Chart, News
- Snapshot
- Company Report
- Quotes
- Charts
- Key Developments
Recent News- Research
- SEC Filings
- Advisor FYI
- CAPS
- StockScouter
- Earnings Estimates
- Analyst Ratings
- Financial Results
- Insider Trading
- Ownership
- Message Board
- Guided Research
- Research Wizard
- Find Stocks
- Stock Screener
- Stock Power Searches
- Top-Rated Stocks
- Related Links
- Quote Watchlist
- Expert Picks
- E-mail & Alerts
- IPO Center
- Message Boards
- Capital Gains Analysis
News resources
| Coca-Cola Co (KO) | 52 stories... |
| Citigroup Inc (C) | 47 stories... |
| Bank of America Corp (BAC) | 44 stories... |
| Apple Inc (AAPL) | 43 stories... |
| Google Inc (GOOG) | 37 stories... |
| advertisement |
Dynavax Technologies Corp: All Recent News
- Dynavax, CFS Bancorp: Early Volume Plays 7:45 AM
- Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session. At TheStreet.com
- Market Report -- In Play (DVAX) 2/8/2010
- Dynavax Technologies announced initiation of a large-scale Phase 3 trial for HEPLISAV Co announced initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of... Briefing.com
- Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM) 2/8/2010
- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed todemonstrate the lot-to-lot consistency of commercial vaccine and tocomplete the safety database for HEPLISAV™, the Company'sinvestigational adult hepatitis B vaccine. This study and the ongoing Phase3 trial in chronic kidney disease patients are directed toward fulfillinglicensure requirements in the U.S., Canada and Europe. HEPLISAV has beenshown in two pivotal Phase 3 trials to enhance protection more rapidly andwith fewer doses than a currently licensed vaccine. Market Wire
- Biotech Market Review for Dynavax Technologies Corp. Issued by... 1/27/2010
- DALLAS, Jan. 27, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company Dynavax Technologies Corp. (Nasdaq:DVAX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision. GlobeNewswire
- UPDATE 2-Dynavax hepatitis C drug shows promise in phase 1 trial 1/26/2010
- ... At Thomson Reuters
- Market Report -- In Play (DVAX) 1/26/2010
- Dynavax Technologies Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection Co announces data from two studies that differentiate SD-101 from standard-of-care as well as emerging... Briefing.com
- Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic... 1/26/2010
- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today data from two studies that differentiate SD-101 fromstandard-of-care as well as emerging treatments for chronic HCV infection.The findings of a Phase 1b clinical trial and an in vitro study of SD-101'smechanism of action show that the second-generation TLR9 agonist (1) iswell tolerated and safe and (2) induces both IFN-lambda and IFN-alpha atconcentrations producing antiviral activity. The data will be presented atthe 45th Annual Meeting of the European Association for the Study of theLiver in Vienna, Austria in... Market Wire
- Dynavax Expands Commercial and Clinical Leadership 1/12/2010
- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the addition of two new senior executives to directkey commercial and clinical activities prior to the launch of HEPLISAV(TM),an investigational adult hepatitis B vaccine. Market Wire
- More News
- Market Report
- News by Symbol
- Today's Investing Articles
- Breaking News
- News by Topic
- News by Industry
- MSNBC News
- Data providers
- Copyright © 2010 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.